Buscar
Congreso SOLACI

Artículos del autor

Dr. Omar Tupayachi

Member of the Editorial Board of solaci.org
Chronic Coronary Syndromes

Polymer-Free vs. Biodegradable Polymer Stents: SORT OUT IX 5-Year Outcomes

In a constant strive to achieve life time management, interventional cardiologists focus on optimizing coronary scaffolds, which...
Dr. Omar Tupayachi -
Left Atrial Apendix Closure

Watchman FLX and Improvement Impact vs. 2.5

Left atrial appendage occlusion (LAAO) represents an effective alternative to oral anticoagulation (OAC) in patients with non-valvular...
Dr. Omar Tupayachi -
Chronic Coronary Syndromes

Chronic Stent Recoil and Its Long-Term Effects

The evolution of stent technology—including new scaffold designs, thinner struts, and more biocompatible polymers—has brought about an...
Dr. Omar Tupayachi -
Chronic Coronary Syndromes

Ischemia by Dobutamine Stress Echocardiography as a Predictor of PCI Efficacy

Patients with coronary artery disease (CAD) or chronic coronary syndromes (CCS) present a challenge in selecting the...
Dr. Omar Tupayachi -
Coronary Disease

EuroPCR 2025 | BALI Trial: Intravascular Lithotripsy vs. Conventional Lesion Preparation in Calcified Lesions

Severely calcified coronary lesions represent a therapeutic challenge and have been associated with higher rates of failed...
Dr. Omar Tupayachi -
Acute coronary syndromes

EuroPCR 2025 | Multivessel PCI in Cardiogenic Shock: A Substudy from the DanGer Shock

Patients with extensive acute myocardial infarctions may develop cardiogenic shock, which has been associated with marked contractile...
Dr. Omar Tupayachi -
Structural Heart Disease

EuroPCR 2025 | Individual Patient Data Meta-analysis of PROTECTED TAVR and BHF PROTECT-TAVI

Stroke remains a significant complication associated with the various transcatheter aortic valve implantation (TAVI) devices currently in...
Dr. Omar Tupayachi -
Chronic Ischemic cardiopathy

EuroPCR 2025 | Angiography- vs. Physiology-Guided PCI in TAVI Candidates (FAITAVI)

Coronary artery disease is present in 50 to 70% of TAVI candidates and over 90% of these...
Dr. Omar Tupayachi -

SOLACI es la organización de referencia del intervencionismo cardiovascular latinoamericano.

Últimas Noticias

Transapical TMVR in High Risk Patients: Intrepid 5-Year Outcomes

Dr. Omar Tupayachi - 0
Moderate to severe mitral valve regurgitation (MR) continues is still a high prevalence condition with bad prognosis, particularly among the elderly with left ventricular...

EMERALD II: Non-Invasive Coronary Anatomy and Physiology (CCTA) in ACS Prediction

Dr. Omar Tupayachi - 0
Despite steady progress in secondary prevention and medical treatment optimization (OMT), acute coronary syndrome (ACS) remains one of the leading causes of cardiovascular morbimortality....

Impact of Balloon Post-Dilation on the Long-Term Durability of Bioprostheses after TAVR

Dr. Juan Manuel Pérez - 0
Balloon post-dilation (BPD) during transcatheter aortic valve replacement (TAVR) allows for the optimization of prosthesis expansion and the reduction of residual paravalvular aortic regurgitation....

Noticias Institucionales

SOLACI Wishes You Happy Holidays

solaci - 0
From the heart, Happy Holidays! The Latin American Society of Interventional Cardiology wishes all its members and the medical community across the continent a very Merry Christmas...

Condolences on the passing of Cristiam Arancibia

solaci - 0
The Latin American Society of Interventional Cardiology deeply mourns the passing of Lic. Cristiam Arancibia, first Director of the Chapter of Technicians and Nurses,...

Watch Again: Pulmonary Embolism in 2025 — Risk Stratification and Novel Therapeutic Approaches

solaci - 0
Our webinar “Pulmonary Embolism in 2025: Risk Stratification and Novel Therapeutic Approaches” is now available to watch. The session took place on November 25,...

Accesos

Adolfo Alsina 2653 · Piso 2H · CABA · Buenos Aires · Argentina · (5411) 4954 7173 · info@solaci.org · solaci.org · Términos de uso -Políticas de privacidad